Back to catalogue
№ 409 21 filings · 2023-03-14 → 2026-08-06

TP ICAP GROUP PLC

TCAP
Financial Services Share price 324p Market cap £2.3bn Overall fit 470 /1000

Partial fit for the strategy — Parameta's OTC data business offers indirect AI-data optionality and Liquidnet shows real operating leverage, valuation is fair-to-modestly-cheap, and the balance sheet is investment-grade. However, this is fundamentally a broking-plus-data business, not an AI-receiver, so the top-band AI thesis is absent.

Fair value range 350p–430p Mid case · £2.8bn
Absolute upside +20.5% vs current market cap
Conviction 4/5 confidence in fair call
Supports the call
  • Very detailed segmental disclosure enabling clean SOTP
  • Consistent 5-period beat/in-line track record with rising margins
  • Two valuation methods converge on £2.5-3.0bn equity
Limits the call
  • Parameta US listing timing and valuation is the key swing factor
  • Group revenue remains volatility- and macro-dependent
Methodology

Sum-of-parts on divisional adjusted EBIT with forward P/E cross-check

In one line · bull case

A cash-generative, market-leading wholesale broker with a hidden data asset (Parameta) whose potential US listing plus record trading momentum and progressive buybacks/dividends make the current valuation fair-to-cheap.

In one line · biggest risk

A return to low-volatility, low-rate market conditions would depress Global Broking activity and remove a key earnings tailwind, particularly if the Parameta listing is delayed further.

Drivers
AI beneficiary 35 /100
Primarily an AI spender internally; Parameta's proprietary OTC dataset has indirect AI-training-data optionality but is not yet monetised as such.
Operating leverage 55 /100
Broker comp is variable but corporate/support costs are fixed; Liquidnet H1 25 showed revenue +15% translating to adjusted EBIT +38%.
Earnings vs expectations 70 /100
Consistent modest-to-material beats across FY23, FY24 and H1 25 with Board 'comfortable' commentary regularly followed by in-line/above outcomes.
Growth momentum 68 /100
Q1 2026 record revenue +13% cc, H1 2025 +9%, and management confident on outlook — accelerating trajectory.
Moat 62 /100
Market-leading share in most Global Broking asset classes plus ~70% share of OTC inter-dealer data via Parameta; network-effect liquidity is durable.
Earnings quality 55 /100
Adjusted EBIT includes ~£40-90m annual significant items (legal, restructuring, amortisation of acquisition intangibles) that flatter reported numbers.
Management quality 65 /100
Five consecutive £30m buybacks in 24 months, progressive dividend (+8% interim), disciplined M&A (Neptune, Aotearoa) with clear capital returns framework.
Cyclicality 55 /100
Revenue benefits from volatility and elevated rates; genuinely counter-cyclical to market calm but exposed to trading volume swings.
Leverage 35 /100
Leverage ratio 1.6x, net cash £867m offsetting most of £780m debt, £250m 2032 notes issued 4x oversubscribed — investment-grade profile.

TP ICAP Group plc (TCAP) — Research Note

Executive summary

TP ICAP is the world's leading wholesale inter-dealer broker, connecting institutional buyers and sellers across financial, energy and commodities markets through four divisions (Global Broking, Energy & Commodities, Liquidnet agency execution, and Parameta Solutions data & analytics). Over 2022-2026 the group has delivered consistent revenue growth (£2.1bn → £2.25bn in FY24, with H1 25 up 9% and Q1 26 revenue at a record £689m, +13%) and adjusted EBIT margin expansion from 13.0% to 15.0% at H1 25, alongside £150m of buybacks in 24 months and rising dividends 2025-08 half-year; 2026-05 trading statement; 2025-03 final results. The single most important valuation point today is the potential US minority listing of Parameta Solutions, a subscription-based (98% recurring), 36-45% EBIT-margin OTC data business that TP ICAP believes is not appropriately reflected in the share price.

Fair value estimate

  • Fair value range: 350p – 430p per share; implied market cap £2,500m – £3,070m
  • Methodology: sum-of-parts on adjusted EBIT with cross-check to forward P/E
  • Key assumptions:
    • Parameta Solutions: FY24 adjusted EBIT £83m, run-rating ~£90-95m in FY25 with mid-teens medium-term revenue growth targeted 2025-03 final results. Valued at 12-15x EBIT reflecting subscription mix, high renewal rates and IPO optionality → £1.1-1.4bn
    • Global Broking + E&C (adj. EBIT ~£260-270m FY24): 7-8x EBIT reflecting recurrence limits and market-driven revenue → £1.8-2.2bn
    • Liquidnet division (adj. EBIT £53m FY24 growing to ~£65-70m run-rate): 7-8x → £370-560m
    • Less small net financial position (net cash £867m less loans £780m less non-current lease liabilities £174m ≈ modestly negative), plus £200m+ organic surplus cash guided across 2026-27 2025-08 half-year
  • Latest disclosed market cap: £2,352m; midpoint FV ~£2,780m ≈ 390p per share
  • Absolute upside from 345.2p to 390p mid: +13% (range: +1% to +25%)
  • View: fair to modestly undervalued. The stock has rallied ~36% from 253p in Feb 2026 to 345p, closing much of the historical discount; the remaining upside depends materially on execution of the Parameta US listing and continued volatility benefiting Global Broking.

Sector context

  • Confirmed sector: Financial Services (ICB Super-Sector), sub-industry: capital markets / brokerage services
  • Quality/growth/leverage profile: in-line to modestly above typical peers. TP ICAP has structurally higher recurring-revenue exposure than pure inter-dealer peers via Parameta (9% of revenue, ~26% of adjusted EBIT), better balance sheet than pre-2020, and market-leading share in most product lines
  • Listed peers: BGC Group (BGC US) — closest peer in global inter-dealer broking; Marex Group (MRX) — energy/commodities broker with data adjacency; Compagnie Financière Tradition (CFT SW) — smaller Swiss-listed IDB peer

Investment thesis

  1. Parameta Solutions is a hidden data-business asset with imminent value-crystallisation optionality: 98% subscription revenue, 5-9% ARR growth, ~40% adjusted EBIT margin, and management is actively pursuing a US minority listing with proceeds largely returned to shareholders. The Board reiterated in Aug 2025 that timing remains under review 2025-08 half-year. Even absent an IPO, Parameta contributes disproportionate high-quality earnings.
  2. Operating and profit momentum is accelerating and shareholder returns are compounding: Q1 2026 delivered record £689m revenue (+13% YoY), Global Broking H1 25 adjusted EBIT +19%, Liquidnet +38%, and management guides to organic generation of >£200m surplus cash across 2026-27, on top of the fifth £30m buyback (fifth in 24 months, total £150m) and the interim dividend +8% to 5.2p in H1 25 and +8% to 5.6p in H1 26 2025-08 half-year; 2026-08 half-year
  3. Valuation still undemanding vs. earnings trajectory: at 345p, the stock trades on ~9-10x FY25E adjusted EPS with a ~5% dividend yield, a leverage ratio of 1.6x, and an investment-grade balance sheet — modest multiples for a business growing high single digits with a rising recurring-revenue share and an unrecognised data business 2026-03 final results; 2025-08 half-year

Key risks

  1. Revenue is highly dependent on market volatility and central bank policy: management repeatedly notes revenues depend on trading volumes and macro conditions; a return to low-volatility / low-rate regime would compress Rates and Global Broking activity 2025-03 final results; 2025-08 half-year. Parameta's growth also moderated to 5% in H1 25 on longer sales cycles 2025-08 half-year
  2. Execution/timing risk on Parameta US listing: the potential minority listing was flagged as "possibly Q2 2025", then delayed following market turbulence, and remains under review — a delay/withdrawal removes a key catalyst and returns focus to more cyclical broking earnings 2025-05 trading statement; 2025-11 trading statement
  3. Legal/regulatory tail risks are recurring and material: multiple ongoing cum-ex, LIBOR/Euribor, CFTC-related and MM Warburg matters; H1 25 significant items totalled £44m (of which £22m general/admin) and legal/regulatory provisions require ongoing judgement 2025-08 half-year; 2026-03 final results

Operating leverage

Operating leverage at TP ICAP is moderate rather than transformational. The cost base is bifurcated: broker compensation (~£1.0bn FY24, or 50% of costs) and other front-office costs (£380m) are largely variable with revenue, while total management & support costs of ~£547m FY24 are more fixed and grew only 1% in constant currency despite inflation 2026-03 final results. This means incremental revenue in Global Broking flows through at roughly the contribution margin (~39%) rather than at 80%+ that a pure software business would deliver. Where the leverage becomes more powerful is at the divisional level: Liquidnet's H1 25 revenue +15% translated to adjusted EBIT +38% (5.7% → 14.0% margin swing) as fixed platform costs stayed flat 2025-08 half-year, and Parameta operates at 36-45% adjusted EBIT margin with subscription revenue where incremental sales are almost pure margin. A 10-20% revenue beat across the group would plausibly add ~30-50% to operating profit given the ~2-3 percentage points of achievable margin expansion — meaningful, but not multi-baggering. Score reflects genuine but capped operational gearing.

Value-trap signals

  • None identified as classic value-trap signals (no declining revenue trend, no dividend cuts, no rising leverage, no repeated guidance misses)
  • Watch items rather than value-trap flags: (i) recurring legal/regulatory provisions across cum-ex and CFTC matters; (ii) ~£40-90m annual significant items which flatter adjusted results relative to reported; (iii) auditor transition (Deloitte → PwC) and prior-year restatements around cost classification and FX presentation, which required careful re-basing

Earnings vs. expectations

  • FY 2023: guided close to CMD targets in Aug 2023; delivered adjusted EBIT £299m (restated) — met/exceeded most divisional CMD targets except Group EBIT margin (revised down at FY22 results); cash conversion 124% vs. c.80% target — beat
  • FY 2024: Board comfortable with expectations at Nov 24 trading update; delivered record adjusted EBIT £324m, +12% cc; final dividend +13% — beat
  • H1 2025: April 25 Q1 update stated Board comfortable with market expectations; H1 delivered record revenue £1,224m and 15.0% adjusted EBIT margin — beat; Nov 25 9M update confirmed FY25 EBIT expectations
  • H1 2026 to date: Q1 26 record revenue +13% cc; Board "comfortable with the outlook for the remainder of the year" 2026-05 trading statement; H1 26 released Aug 6 2026 — market inferred to be on-track
  • Pattern: consistent modest-to-material beats or in-line-plus outcomes across five reporting periods, driven by both favourable volatility conditions and internal cost discipline. Rewards a "beats consensus more than misses" trend score.

Conviction

Conviction: 4 (high) in the fair-value range as an appropriately conservative-to-fair band around current price.

  • Anchors: (i) very comprehensive disclosure with segmental, contribution-margin and cost-classification detail; (ii) five clean, consistent reporting cycles with confirmable revenue and EBIT growth; (iii) two independent valuation approaches (SOTP and forward P/E) converge on £2.5-3.0bn equity value
  • Limiting factors: (i) Parameta valuation is the swing factor and depends on whether/how a US listing prices, which could rerate the whole group meaningfully in either direction; (ii) FY26+ earnings are still market-dependent on trading volumes and volatility persisting

Driver scoring rationale

The AI-beneficiary case is weak: TP ICAP is primarily an AI spender (Amazon Q Developer, code-review AI, Fusion cloud migration), not a receiver. The nearest AI-adjacent asset is Parameta's proprietary OTC dataset — potentially valuable to train pricing/risk models — but this is not yet monetised as an AI-data-licensing revenue line. Operating leverage is moderate (broker comp is variable, but corporate costs are fixed). Valuation is fair. Balance sheet is investment-grade with net cash and leverage 1.6x.

Filings consulted · 24

Every document the LLM read for this note. Click any row to open the source.

  1. 2026-08-06Half Year Financial Report2026-08-06_9707286_half-year-financial-report.md0.90
  2. 2026-05-13Trading Statement2026-05-13_9565119_trading-statement.md0.85
  3. 2026-05-13Result OF Agm2026-05-13_9567090_result-of-agm.md0.30
  4. 2026-04-092025 Annual Report And Notice OF 2026 Agm2026-04-09_9512376_2025-annual-report-and-notice-of-2026-agm.md0.95
  5. 2026-03-12Final Results2026-03-12_9470273_final-results.md0.85
  6. 2025-11-05Trading Statement2025-11-05_9212812_trading-statement.md0.72
  7. 2025-08-06Half Year Report2025-08-06_9030483_half-year-report.md0.58
  8. 2025-05-14Trading Statement2025-05-14_8876318_trading-statement.md0.55
  9. 2025-05-14Result OF Agm2025-05-14_8878664_result-of-agm.md0.20
  10. 2025-04-11Notice OF Agm2025-04-11_8827258_notice-of-agm.md0.20
  11. 2025-03-11Final Results2025-03-11_8772355_final-results.md0.65
  12. 2024-11-05Trading Statement2024-11-05_8529343_trading-statement.md0.55
  13. 2024-08-07Half Year Report2024-08-07_8352978_half-year-report.md0.41
  14. 2024-05-15Trading Statement2024-05-15_8197025_trading-statement.md0.38
  15. 2024-04-112023 Annual Report And Notice OF 2024 Agm2024-04-11_8133110_2023-annual-report-and-notice-of-2024-agm.md0.43
  16. 2024-03-12Final Results2024-03-12_8082246_final-results.md0.45
  17. 2023-10-31Trading Statement2023-10-31_7849023_trading-statement.md0.38
  18. 2023-08-09Half Year Report Replacement2023-08-09_7686502_half-year-report-replacement.md0.23
  19. 2023-08-09Half Year Report2023-08-09_7684499_half-year-report.md0.23
  20. 2023-05-17Trading Statement2023-05-17_7530025_trading-statement.md0.21
  21. 2023-05-17Result OF Agm2023-05-17_7531663_result-of-agm.md0.07
  22. 2023-04-04Notice OF Agm And Committee Membership Changes2023-04-04_7427996_notice-of-agm-and-committee-membership-changes.md0.07
  23. 2023-03-222022 Annual Report And Accounts2023-03-22_7277700_2022-annual-report-and-accounts.md0.24
  24. 2023-03-14TP Icap Group Plc Final Results2023-03-14_7432855_tp-icap-group-plc-final-results.md0.25

This research note was authored by a large language model after reading 21 regulatory filings published between 2023-03-14 and 2026-08-06. Each citation refers to a specific RNS announcement in the underlying data set. The note is an opinion, not advice. Do your own work before risking capital.